Calcitonin salmon
As of the edition of 20 October 2026, Calcitonin salmon is a protein: marketed, first approved in 1982 (US); acts on CALCR; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1983
- Kind
- Protein
- Brand name
- Calcimar
- First approved
- 1 January 1982 (US)
- Approvals on record
- 8 in 2 regions
- Holder of the most recent approval
- Upsher-Smith; 5 holders in all
- Withdrawn from market
- 29 October 2008 (in some regions)
- Registered trials
- 10, 2 stopped early
- Disease areas
- Bones, joints and muscles; Nutrition and metabolism; Inherited and neonatal; Nervous system; Pregnancy and women's health; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Calcitonin salmon.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CALCR | Calcitonin receptor | P30988 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 1 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 3 | 2 | 0 | 1 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novartis | Later holder and Lead sponsor of trials | 1986 to now |
| Unigene | Later holder | 2005 to now |
| Viatris | Acquired holder | 2015 to now |
| Upsher-Smith | Acquired holder | 2017 to now |
| Saptalis Pharmaceuticals | Acquired holder | 2026 to now |
| Sanofi | Applicant |